Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

UBS downgrades SSP to 'sell', shares slide

(Sharecast News) - SSP was under the cosh on Friday after a downgrade to 'sell' from 'neutral' at UBS, which said that mid-term consensus screens as stretched in light of upcoming headwinds. The bank said weak volumes and lower near-term capacity put consensus at risk.

It noted that the share price has risen by around 12% since the company's first-half results presentation in May, in part owing to the market's positive reaction to the recent pricing of the group's Indian IPO.

"However, UBS Evidence Lab data indicates a step down in airline capacity growth in 3Q, with industry data indicating a further significant reduction in capacity growth in 4Q," it said.

"With the slower pace of growth and combined with a stronger GBP we see downside risk to consensus estimates with our FY26 EBIT and EPS forecasts now 7% and 10% below consensus respectively.

"As we now see consensus estimates as unlikely to be achieved, we downgrade our rating to sell."

UBS lifted its price target on the stock to 170p from 165p.

At 0910 BST, the shares were down 6.9% at 174.95p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.